Browse SLC33A1

Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Multi-pass membrane protein
Domain PF13000 Acetyl-coenzyme A transporter 1
Function

Probable acetyl-CoA transporter necessary for O-acetylation of gangliosides (PubMed:9096318). Negatively regulates BMP signaling (PubMed:25402622).

> Gene Ontology
 
Biological Process GO:0006818 hydrogen transport
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0015672 monovalent inorganic cation transport
GO:0015876 acetyl-CoA transport
GO:0015916 fatty-acyl-CoA transport
GO:0015992 proton transport
GO:0030509 BMP signaling pathway
GO:0051181 cofactor transport
GO:0051182 coenzyme transport
GO:0060395 SMAD protein signal transduction
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0072348 sulfur compound transport
GO:1901337 thioester transport
Molecular Function GO:0008521 acetyl-CoA transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015295 solute:proton symporter activity
GO:0022804 active transmembrane transporter activity
GO:0051184 cofactor transporter activity
GO:0051185 coenzyme transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00604 Glycosphingolipid biosynthesis - ganglio series
hsa01100 Metabolic pathways
Reactome R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425397: Transport of vitamins, nucleosides, and related molecules
Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC33A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC33A1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -1.86; FDR: 0.02370 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC33A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0310.913
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0670.969
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.10.936
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0110.963
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2450.882
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2830.894
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0770.851
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0380.981
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2240.895
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2870.842
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3530.861
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0580.244
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC33A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC33A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC33A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC33A1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC33A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC33A1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC33A1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC33A1
Namesolute carrier family 33 (acetyl-CoA transporter), member 1
Aliases AT-1; ACATN; SPG42; acetyl-Coenzyme A transporter; spastic paraplegia 42 (autosomal dominant); CCHLND; Solut ......
Chromosomal Location3q25.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC33A1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.